Nicole L. Fung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicole L. Fung has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Luk
Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
3 shared publications - Darshan H. Brahmbhatt
Ted Rogers Centre for Heart Research, University of Toronto, Toronto, Canada
3 shared publications - Fernando Luis Scolari
Hospital de Clínicas de Porto Alegre
3 shared publications - Filio Billia
Toronto General Hospital Research Institute, Toronto Canada
3 shared publications - Heather Joan Ross
Department of Medicine, Division of Cardiology, University of Toronto, Peter Munk Cardiac Centre , Toronto
3 shared publications Madison Otsuki
Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario
3 shared publications
Latest Publications
- Open Access
- 9 February 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (3) , 2077-2086
Heart Failure Decompensation with Cardiogenic Shock Exhibits Distinct Sequential Inflammatory Profiles
Aims: The inflammatory profile of cardiogenic shock (CS) after myocardial infarction affects outcomes; however, little is known about the impact of inflammatory changes in CS caused by acute decompensated heart failure (ADHF-CS). We measured levels of inflammatory cytokines in patients with ADHF-CS admitted to a cardiac intensive care unit (CICU). Methods: We identified patients admitted to our CICU with ADHF-CS who had consented to having biospecimens stored. We identified two comparator groups of patients with HF seen as outpatients with stored biospecimens: firstly, those who had no history of decompensation and did not develop CS during follow-up after sample acquisition (stable HF), and secondly, a group of patients who developed CS during follow-up (pre-CS). All samples underwent 48-plex cytokine and white blood cell differential testing with the differences between groups analysed by comparing means. Results: Eighty-four ADHF-CS patients were identified who had samples obtained at a median of 2 [inter-quartile range (IQR) 0–7] days after CICU admission. Thirty-six pre-CS outpatients had samples taken 137 (IQR 41–258) days before admission with CS, and 338 stable HF control patients were included. Cytokine profiles differed between ADHF-CS and stable HF. Patients with CS had higher pro-inflammatory cytokine levels [including interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8)] and total white cell counts than stable HF patients. Analysis of the pre-CS outpatient group suggested an intermediate stage in subacute transition to CS. Conclusions: ADHF-CS is characterized by high levels of pro-inflammatory cytokines and total white count, compared with ambulatory HF. Decompensation from HF has two distinct inflammatory phases that may help identify outpatients at risk of CS.
- 9 February 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (3) , 2077-2086
Open AccessHeart Failure Decompensation with Cardiogenic Shock Exhibits Distinct Sequential Inflammatory Profiles
Aims: The inflammatory profile of cardiogenic shock (CS) after myocardial infarction affects outcomes; however, little is known about the impact of inflammatory changes in CS caused by acute decompensated heart failure (ADHF-CS). We measured levels of inflammatory cytokines in patients with ADHF-CS admitted to a cardiac intensive care unit (CICU). Methods: We identified patients admitted to our CICU with ADHF-CS who had consented to having biospecimens stored. We identified two comparator groups of patients with HF seen as outpatients with stored biospecimens: firstly, those who had no history of decompensation and did not develop CS during follow-up after sample acquisition (stable HF), and secondly, a group of patients who developed CS during follow-up (pre-CS). All samples underwent 48-plex cytokine and white blood cell differential testing with the differences between groups analysed by comparing means. Results: Eighty-four ADHF-CS patients were identified who had samples obtained at a median of 2 [inter-quartile range (IQR) 0–7] days after CICU admission. Thirty-six pre-CS outpatients had samples taken 137 (IQR 41–258) days before admission with CS, and 338 stable HF control patients were included. Cytokine profiles differed between ADHF-CS and stable HF. Patients with CS had higher pro-inflammatory cytokine levels [including interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8)] and total white cell counts than stable HF patients. Analysis of the pre-CS outpatient group suggested an intermediate stage in subacute transition to CS. Conclusions: ADHF-CS is characterized by high levels of pro-inflammatory cytokines and total white count, compared with ambulatory HF. Decompensation from HF has two distinct inflammatory phases that may help identify outpatients at risk of CS.
- Open Access
- 20 January 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 40 (7) , 1352-1354
Infected Pseudoaneurysm of an Outflow Graft After Left Ventricular Assist Device Insertion
- 20 January 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 40 (7) , 1352-1354
Open AccessInfected Pseudoaneurysm of an Outflow Graft After Left Ventricular Assist Device Insertion
- Open Access
- 16 August 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 3078-3086
Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients
- 16 August 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 3078-3086
Open AccessClonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients
- 10 July 2022
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (9) , 1573-1582
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock
Aims: Cardiogenic shock (CS) with variable systemic inflammation may be responsible for patient heterogeneity and the exceedingly high mortality rate. Cardiovascular events have been associated with clonal haematopoiesis (CH) where specific gene mutations in haematopoietic stem cells lead to clonal expansion and the development of inflammation. This study aims to assess the prevalence of CH and its association with survival in a population of CS patients in a quaternary centre. Methods and results: We compared the frequency of CH mutations among 341 CS patients and 345 ambulatory heart failure (HF) patients matched for age, sex, ejection fraction, and HF aetiology. The association of CH with survival and levels of circulating inflammatory cytokines was analysed. We detected 266 CH mutations in 149 of 686 (22%) patients. CS patients had a higher prevalence of CH‐related mutations than HF patients (odds ratio 1.5; 95% confidence interval [CI] 1.0–2.1, p = 0.02) and was associated with decreased survival (30 days: hazard ratio [HR] 2.7; 95% CI 1.3–5.7, p = 0.006; 90 days: HR 2.2; 95% CI 1.3–3.9, p = 0.003; and 3 years: HR 1.7; 95% CI 1.1–2.8, p = 0.01). TET2 or ASXL1 mutations were associated with lower survival in CS patients at all time‐points ( p ≤ 0.03). CS patients with TET2 mutations had higher circulating levels of SCD40L, interferon‐γ, interleukin‐4, and tumour necrosis factor‐α ( p ≤ 0.04), while those with ASXL1 mutations had decreased levels of CCL7 ( p = 0.03). Conclusions: Cardiogenic shock patients have high frequency of CH, notably mutations in TET2 and ASXL1 . This was associated with reduced survival and dysregulation of circulating inflammatory cytokines in those CS patients with CH.
- 10 July 2022
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (9) , 1573-1582
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock
Aims: Cardiogenic shock (CS) with variable systemic inflammation may be responsible for patient heterogeneity and the exceedingly high mortality rate. Cardiovascular events have been associated with clonal haematopoiesis (CH) where specific gene mutations in haematopoietic stem cells lead to clonal expansion and the development of inflammation. This study aims to assess the prevalence of CH and its association with survival in a population of CS patients in a quaternary centre. Methods and results: We compared the frequency of CH mutations among 341 CS patients and 345 ambulatory heart failure (HF) patients matched for age, sex, ejection fraction, and HF aetiology. The association of CH with survival and levels of circulating inflammatory cytokines was analysed. We detected 266 CH mutations in 149 of 686 (22%) patients. CS patients had a higher prevalence of CH‐related mutations than HF patients (odds ratio 1.5; 95% confidence interval [CI] 1.0–2.1, p = 0.02) and was associated with decreased survival (30 days: hazard ratio [HR] 2.7; 95% CI 1.3–5.7, p = 0.006; 90 days: HR 2.2; 95% CI 1.3–3.9, p = 0.003; and 3 years: HR 1.7; 95% CI 1.1–2.8, p = 0.01). TET2 or ASXL1 mutations were associated with lower survival in CS patients at all time‐points ( p ≤ 0.03). CS patients with TET2 mutations had higher circulating levels of SCD40L, interferon‐γ, interleukin‐4, and tumour necrosis factor‐α ( p ≤ 0.04), while those with ASXL1 mutations had decreased levels of CCL7 ( p = 0.03). Conclusions: Cardiogenic shock patients have high frequency of CH, notably mutations in TET2 and ASXL1 . This was associated with reduced survival and dysregulation of circulating inflammatory cytokines in those CS patients with CH.